Volume 6, Issue 3, September 2018, Page: 56-60
Prevalence of Sexual Dysfunction in Females with and Without Schizophrenia
Pallavi Abhilasha, Department of Psychiatry, SRM Medical College & Research Centre, Tamilnadu, India
Mrinalini Reddy, Department of Psychiatry, SRM Medical College & Research Centre, Tamilnadu, India
Rajkumar Ramanathan, Department of Psychiatry, SRM Medical College & Research Centre, Tamilnadu, India
Thirunavukarasu Manickam, Department of Psychiatry, SRM Medical College & Research Centre, Tamilnadu, India
Sivabalan Elangovan, Department of Psychiatry, SRM Medical College & Research Centre, Tamilnadu, India
Received: Jun. 1, 2018;       Accepted: Jul. 3, 2018;       Published: Aug. 1, 2018
DOI: 10.11648/j.ajpn.20180603.11      View  598      Downloads  46
Abstract
INTRODUCTION- Schizophrenia is an illness that may influence every aspect of the person’s life. Rates of female sexual dysfunction (FSD) in schizophrenia the rates reported have been between 30 and 80%. The aim was to identify attribution (locus of control) and sexual dysfunction among female with schizophrenic disorder and females without schizophrenia and to study and to compare the sexual dysfunction and attribution in schizophrenic and non-schizophrenic women. METHODS- This was a cross sectional, hospital-based study and was approved by the Institutional Ethics Committee of SRM Medical college and health sciences. Women between the ages of 21 to 45 years, diagnosed with schizophrenia by ICD 10 criteria (World Health Organization, 1992) attending the outpatient services, who were under remission, and were in marital relationship for at least six months were approached for the study. Schizophrenia was assessed using PANSS while sexual dysfunction in females was assessed using female sexual functioning index. Sexual attribution was assessed by using Rotter’s locus of control. RESULTS- 45 women belonging to cases had sexual dysfunction as assessed by FSFI whilst 13 had had scored for sexual dysfunction is the control group. 5 in the cases and 37 in controls did not have sexual dysfunction. X2 test was carried out and the difference was very highly statistically significant at 0.001level. A very high frequency of sexual dysfunction in this group calls for added focus in to this aspect for a better quality of life for the patient. The relationship between locus of control, sexual dysfunction as assessed by FSFI and PANSS scores where higher scores denote a severe form of illness were subjected to co-relation analysis. Locus of control is identified to be external when the scores are higher than the cut-off point. CONCLUSION-Sexual dysfunction is one of the aspects which affect the overall quality of life and needs to be studied on a larger sample and the relationship between illness related, treatment related and environment related factors need to be studied. Individual disturbances in the various aspects of sexual dysfunction also need to be studied.
Keywords
Sexual Dysfunction, Females, Attribution, Schizophrenia, Prevalence
To cite this article
Pallavi Abhilasha, Mrinalini Reddy, Rajkumar Ramanathan, Thirunavukarasu Manickam, Sivabalan Elangovan, Prevalence of Sexual Dysfunction in Females with and Without Schizophrenia, American Journal of Psychiatry and Neuroscience. Vol. 6, No. 3, 2018, pp. 56-60. doi: 10.11648/j.ajpn.20180603.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
M. Simiyon et al, Sexual dysfunction among women with Schizophrenia—A cross sectional study from India, Asian Journal of Psychiatry AJP 24 (2016) 93–98
[2]
McCabe, M. P., Sharlip, I. D., Lewis, R., Atalla, E., Balon, R., Fisher, A. D., Laumann, E., Lee, S. W., Segraves, R. T., 2016b. Incidence and Prevalence of Sexual Dysfunction in Women and Men: A Consensus Statement from the Fourth International Consultation on Sexual Medicine 2015Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. J. Sex. Med. 13, 144–152. doi:http://dx.doi.org/10.1016/j.jsxm.2015.12.034
[3]
Baggaley, M., 2008. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum. Psychopharmacol. 23, 201–209. doi:http://dx.doi.org/10.1002/hup.924
[4]
Fujii, A., Yasui-Furukori, N., Sugawara, N., Sato, Y., Nakagami, T., Saito, M., Kaneko, S., 2010. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 288–293. doi: http://dx.doi.org/10.1016/j.pnpbp.2009.11.022
[5]
Üçok, A., _Incesu, C., Aker, T., Erkoç, Ş., 2007. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur. Psychiatry 22, 328–333. doi: http://dx.doi.org/10.1016/j.eurpsy.2007.01.001
[6]
Varghese, K. M., Bansal, R., Kekre, A. N., Jacob, K. S., 2012. Sexual dysfunction among young married women in southern India. Int. Urogynecol. J. 23, 1771–1774. doi: http://dx.doi.org/10.1007/s00192-012-1782-3
[7]
Ajit avasthi et al., Sexual Behavior of Married Young Women: A Preliminary Study from North India. Indian J Community Med. 2008 Jul; 33(3): 163–167.
[8]
Lucca, J., Ramesh, M., Ram, D., Kurian, J., Mathew, N., 2016. Psychotropic medication-induced sexual dysfunction and its interference with patient0s daily performance: a cross-sectional study. Egypt. J. Psychiatry 37, 36. doi:http://dx. doi.org/10.4103/1110-1105.180268
[9]
Nagaraj, A. K. M., Pai, N. B., Rao, S., 2009. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. Indian J. Psychiatry 51, 265–271. doi:http://dx.doi.org/10.4103/0019-5545.58291
[10]
Nebhinani, N., Grover, S., Avasthi, A., 2012. Sexual dysfunction in male subjects receiving trifluoperazine, risperidone, or olanzapine: rates vary with assessment questionnaire. Sexual dysfunction in male subjects receiving trifluoperazine, risperidone, or olanzapine: rates vary with assessment questionnaire. Prim. Care Companion CNS Disord. 14 doi:http://dx.doi.org/ 10.4088/pcc.11m01199
[11]
Thangadurai, P., Gopalakrishnan, R., Kuruvilla, A., Jacob, K. S., Abraham, V. J., Prasad, J., 2014. Sexual dysfunction among men in secondary care in southern India: Nature, prevalence, clinical features and explanatory modelsSexual dysfunction among men in secondary care in southern India: nature, prevalence, clinical features and explanatory models. Natl. Med. J. (India) 27, 198–201.
[12]
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., Weinberger, D. R., 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162, 441–449. doi:http://dx.doi.org/10.1176/appi. ajp.162.3.441
Browse journals by subject